The risk of sudden cardiac death in patients with non-ST elevation acute coronary syndrome and prolonged QTc interval: Effect of ranolazine

Europace

Volumn 15, Issue 3, 2013, Pages 429-436

  Karwatowska Prokopczuk, Ewa ^a   Wang, Whedy ^a   Cheng, Mei L ^a   Zeng, Dewan ^a   Schwartz, Peter J ^b   Belardinelli, Luiz ^a  

^a GILEAD SCIENCES   (United States)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Acute coronary syndrome; QTc prolongation; Ranolazine; Sudden cardiac death

Indexed keywords

ANTIARRHYTHMIC AGENT; PLACEBO; RANOLAZINE;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HAZARD RATIO; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SUDDEN DEATH;

ACETANILIDES; ACUTE CORONARY SYNDROME; AGED; CARDIOVASCULAR AGENTS; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LONG QT SYNDROME; MALE; MULTIVARIATE ANALYSIS; PIPERAZINES; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84874409862     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eus400     Document Type: Article

References (32)

1. Chugh SS, Jui J, Gunson K, Stecker EC, John BT, Thompson B et al. Current burden of sudden cardiac death: Multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004; 44:1268-75.
2. Goldberger JJ, Cain ME, Hohnloser SH, Kadish AH, Knight BP, Lauer MS et al. American Heart Association; American College of Cardiology Foundation; Heart Rhythm Society: American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: A scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008;118:1497-518.
3. Podrid PJ, Myerburg RJ. Epidemiology and stratification of risk for sudden cardiac death. Clin Cardiol 2005;28:I3-11.
4. Arshad A, Mandava A, Kamath G, Musat D. Sudden cardiac death and the role of medical therapy. Prog Cardiovasc Dis 2008;50:420-38.
5. Piccini JP, Berger JS, O'Connor CM. Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials. Eur Heart J 2009; 30:1245-53.
6. Julian DG, Camm AJ, Frangin G, Janse MJ, Munoz A, Schwartz PJ et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 1997;349:667-74.
7. Stecker EC, Vickers C,Waltz J, Socoteanu C, John BT, Mariani R et al. Populationbased analysis of sudden cardiac death with and without left ventricular systolic dysfunction: Two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006;47:1161-6.
8. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M et al. Risk stratification in the long-QT syndrome. N Engl J Med 2003;348:1866-74.
9. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978;57:1074-7.
10. Straus SM, Kors JA, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006;47:362-7.
11. Chugh SS, Reinier K, Singh T, Uy-Evanado A, Socoteanu C, Peters D et al. Determinants of prolonged QT interval and their contribution to sudden death risk in coronary artery disease: The Oregon Sudden Unexpected Death Study. Circulation 2009;119:663-70.
12. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003;24:619-25.
13. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J et al. Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA 2004;291:309-16.
14. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J et al. MARISA Investigators: Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43:1375-82.
15. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: The ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566-75.
16. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006;113:2462-72.
17. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904-10.
18. Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 2011;8:1281-90.
19. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-52.
20. Scirica BM, Morrow DA, Karwatowska-Prokopczuk E, Hedgepeth CM, Wang W, Qin J et al. Ventricular arrhythmias following non-ST segment elevation ACS and the relationship with sudden cardiac death in the MERLIN-TIMI 36 trial. J Am Coll Cardiol 2009;53:A121.
21. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Skene A, McCabe CH, Braunwald E. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial. Am Heart J 2006;151:1186 e1-9.
22. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S et al. MERLIN-TIMI 36 Trial Investigators: Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial. JAMA 2007;297:1775-83.
23. WHO. Regional Office for Europe Report of a Working Group on Ischaemic Heart Disease Registers. Parts I and II In Euro 5010. Copenhagen: World Health Organization; 1969.
24. Antman EM, Cohen M, Bernink PL, McCabe CH, Horacek T, Papuchis G et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostification and therapeutic decision making. JAMA 2000;284:835-42.
25. Morrow DA, de Lemos JA, Sabatine MS, Demopoulos LA, DiBattiste PM, McCabe CH et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST elevation MI: BNP and prognosis in TACTICS-TIMI 18. J Am Coll Cardiol 2003;41:1264-72.
26. Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical characteristics & utilization of biochemical markers in acute coronary syndromes. Circulation 2007;115:e356-75.
27. Piccini JP, Zhang M, Pieper K, Solomon SD, Al-Khatib SM, Van de Werf F et al. Predictors of sudden cardiac death change with time after myocardial infarction:- results from the VALIANT trial. Eur Heart J 2010;31:211-21.
28. Atkinson AC. A note on the generalized information criterion for choice of a model. Biometrika 1980;67:413-8.
29. Schwarz G. Estimating the dimension of a model. Ann Stat 1978;6:461-4.
30. Klein JP, Moeschberger ML. Survival Analysis. New York: Springer Science+ Business Media, Inc.; 2003.
31. Davey P. QT interval and mortality from coronary artery disease. Prog Cardiovasc Dis 2000;42:359-84.
32. Schwartz PJ. Clinical significant of QT prolongation: A personal view. In: Butrous GS, Schwartz PJ, eds. Clinical aspects of ventricular repolarization. London: Farrand Press, 1989. p343-56.